CROSSINGS
Brief description of study
The aim of this global Phase III study is to investigate the use of tezepelumab as a treatmentfor patients with EoE. This study will evaluate the efficacy and safety of tezepelumab 210 mgevery 4 weeks (Q4W) and tezepelumab 420 mg Q4W administered subcutaneously (SC) usingan accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent participants with EoE.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
